Pfizer’s Elrexfio improves progression-free survival in Phase 3 multiple myeloma trial

• Pfizer’s Elrexfio met the primary endpoint in the Phase 3 MagnetisMM-32 trial, outperforming standard regimens in relapsed or refractory multiple myeloma.
• Treatment reduced the risk of disease progression or death in patients previously treated with anti-CD38 therapy and lenalidomide.
• No new safety signals emerged, though severe infections were more frequent with Elrexfio than with comparator treatments.
• The findings support potential use in earlier treatment lines; planned submissions to global health authorities will seek regulatory review.
• Topline results were announced; detailed findings will be presented at a future medical meeting and submitted for publication.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pfizer Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610270645BIZWIRE_USPR_____20261027_BW750216) on October 27, 2026, and is solely responsible for the information contained therein.